San Diego, February 27th

Welcome to hubXchange’s Immuno-Oncology Xchange San Diego 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies, through a series of roundtable discussions. 
Discussion topics will cover Immune Biomarkers, Translational Research, Clinical Development, and Cell Therapies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Handlery Hotel San Diego, 950 Hotel Circle North, San Diego CA 92108


  • Predictive biomarkers for IO treatment used in clinical practice now and in the future
  • The rise of spatial omics technologies and their potential for new biomarker discovery
  • Translational strategies to develop clinically safe and effective immune cell engagers
  • How to select the right translational screening model to monitor IO agents
  • Early signals of efficacy, biomarkers and confidence in early clinical I/O trials
  • How to maximize clinical success: Patient selection strategies beyond target expression
  • Exploring different cellular modalities
  • TME-targeting combinations – improving efficacy

Full Xchange Agenda

Click on each track for detailed agenda

Immune Biomarkers

Titles and Bullets
8:00 – 8:30
8:30 – 9:00

Opening Keynote Presentation

9:05 – 10:05

Overcoming Limited Tumor Tissue Availability: Biomarker Identification in Blood for Improved Cancer Diagnosis and Monitoring

  • Advantages and Limitations of Each Approach: What are the pros and cons of each approach?
  • Comprehensive Blood-Based Assessment: Can blood measurements comprehensively address all biomarker and monitoring questions?
  • Validation of Blood-Based Approaches: Is it necessary to evaluate both approaches for validation when considering a blood-based approach exclusively?
  • Mandatory Tumor Tissue Biopsies in Clinical Trials: Can tumor tissue biopsies be a mandatory requirement in clinical trials for any indications?

Sonia Feau is Director of Biology at Onchilles Pharma and is responsible for managing activities related to the overall execution of R&D initiatives to move innovative therapeutic drug candidates into the clinic and advance Onchilles’ platform and future product portfolios.
Sonia has 20 years of immuno-oncology experience. Prior to Onchilles Pharma, Sonia worked at Oncorus where she led the Immunology group responsible for designing, optimizing and evaluating new immune enhancer payloads to be expressed by oncolytic viruses, at Merck & Co. and Merrimack Pharmaceuticals, she proposed and evaluated several new immuno-oncology targets.
Sonia’s experience in Immunology spans both innate and adaptive immune responses. She received her post-doctoral training at the La Jolla Institute for Immunology in San Diego, where she studied CD8 memory T cells. Sonia received her Ph.D. in Immunology and Biotechnology from the University of Milano-Bicocca, Italy and University Toulouse III, France studying dendritic cells biology.

Sonia Feau
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:40 – 11:10
1-2-1 Meetings/Networking Break
11:10 – 11:20
Morning Refreshments
11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20
Networking Lunch
13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55
1-2-1 Meetings/Networking Break
14:55 – 15:05

Afternoon Refreshments

15:05 – 15:35

Poster Session by Bio-Rad

Anti-TIGIT antibody discovery

15:40 – 16:40

Pharmacodynamic and predictive biomarkers: Choosing the right strategy from preclinical to clinical stages

16:40 – 17:40
Drinks-Canape Reception


Immuno-Oncology Xchange | San Diego 2024